

**Remarks**

Claims 17 and 27 are pending in this application. No claims have been allowed.

In their Reply filed on May 20, 2011, Applicants amended the Specification to insert cross-reference information and claim for benefit of priority. Although no acknowledgment of this amendment or claim for benefit was provided in the Office Action dated June 3, 2011, Applicants assume the amendment has been entered.

**Rejection of Claims 17 and 27 under 35 U.S.C. §112, First Paragraph**

Claims 17 and 27 were rejected under 35 U.S.C. §112, first paragraph as allegedly failing to comply with the written description requirement for “solvates” of the specified compounds. While Applicants do not acquiesce to the merits of the rejection, in order to advance prosecution, Applicants have amended claim 17 to delete the phrase “or solvate.”

It is respectfully requested that the rejection be withdrawn and the application passed to issue. If there are any further matters that may properly be addressed through a telephone conversation, the Examiner is invited to contact Applicants undersigned attorney.

Respectfully submitted,

/John C. Demeter/  
John C. Demeter  
Attorney for Applicants  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

August 10, 2011